Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,234

Shortly after publishing a paper demonstrating how its artificial intelligence programs could generate viable lead compounds in just a few weeks, Insilico Medicine has signed a dual-program discovery collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical worth up to $200 million.

Focused on previously undruggable targets in triple-negative breast cancer, the deal includes an upfront payment along with potential milestones and sales-based royalties pegged to any eventual products.

“We are very pleased to establish the partnership with Insilico Medicine, entering the new era of AI-enabled drug development,” Wenyu Xia, general manager of the China-based pharma company, said in a statement. “We look forward to a long-term partnership with Insilico Medicine.”

Read more | >

Which disease will you die of first? If you survive that one, which disease is next in line? If we are kept alive but unwell and continue to practice medicine the way we do today, we will all get a long list of diseases — we are just going to be stacking up more and more layers of treatment, becoming more and more unhappy and spending more and more time at the doctors.

Many thanks for watching!

Consider supporting SciFuture by:
a) Subscribing to the SciFuture YouTube channel: http://youtube.com/subscription_center?add_user=TheRationalFuture b) Donating
- Bitcoin: 1BxusYmpynJsH4i8681aBuw9ZTxbKoUi22
- Etherium: 0xd46a6e88c4fe179d04464caf42626d0c9cab1c6b
- Patreon: https://www.patreon.com/scifuture c) Sharing the media SciFuture creates: http://scifuture.org

Kind regards.
Adam Ford
- Science, Technology & the Future.

Read more | >

Some researchers continue to insist that simulating neuroscience with computers is the way to go. Others, like me, view these efforts as doomed to failure because we do not believe consciousness is computable. Our basic argument is that brains integrate and compress multiple components of an experience, including sight and smell – which simply can’t be handled in the way today’s computers sense, process and store data.

Brains don’t operate like computers

Living organisms store experiences in their brains by adapting neural connections in an active process between the subject and the environment. By contrast, a computer records data in short-term and long-term memory blocks. That difference means the brain’s information handling must also be different from how computers work.

Read more | >

The core of what we do at Nanalyze is to tell our readers all they need to know about investing in emerging technologies. Sometimes that story is much, much bigger, and what we’re really talking about is investing in emerging industries. NewSpace is one example, launching about 15 years ago with the emergence of companies like SpaceX and Virgin Galactic. It’s probably only within the last five years that the NewSpace industry has achieved real liftoff, with dozens of startups doing everything from offering launch services to building satellites to developing business analytics from space-based imagery. While we may one day end up living on Mars, we’re more interested in living a long and fruitful life right here on Mother Earth, despite the specter of cancer and dementia. An entire industry is coalescing around human longevity, promising to beat these age-related diseases and extend our lives to biblical proportions.

We’ve been covering the topic of life extension for more than five years, beginning with a profile on an anti-aging company called Human Longevity Inc, whose founders include billionaire serial entrepreneur Peter Diamandis and J. Craig Venter, a leading genomics expert. More recently, we introduced you to nine companies developing products in regenerative medicine, a broad category that refers to restoring the structure and function of damaged tissues or organs. We also tackled the more controversial topic of young blood transfusions earlier this year, as well as covered the 2019 IPO of Precision BioSciences (DTIL), a gene-editing company that wants to fight disease and re-engineer food.

Read more | >

The industry science behind EMF radiation is more corrupt than that of climate science, and has been so since the beginning. With the imminent rollout of 5G, no scientific studies have been done on exposure to humans at any distance. ⁃ TN Editor.

Neurosurgeon and researcher Dr. Leif Salford has conducted many studies on radio frequency radiation and its effects on the brain. Dr. Salford called the potential implications of some of his research “terrifying.” Some of the most concerning conclusions result from the fact that the weakest exposure levels to wireless radiation caused the greatest effect in causing the blood brain barrier to leak.

Since he began his line of research in 1988, Dr. Leif Salford and his colleagues at Lund University Hospital in Sweden has exposed over 1,600 experimental animals to low-level radiation. Their results were consistent and worrisome: radiation, including that from cell phones, caused the blood-brain barrier–the brain’s first line of defense against infections and toxic chemicals–to leak.

Read more | >

Harry Potter’s ‘invisibility cloak’ appears closer to reality as Canadian camouflage manufacturer Hyperstealth Biotechnology has applied for patents on its ‘Quantum Stealth’ material.

The ‘inexpensive and paper-thin’ technology works by bending light around a target to either alter its position or make it vanish altogether, leaving only the background visible. It is touted to be able to obscure the positions of heavy artillery, ground troops or even entire buildings from certain viewpoints.

Get the latest headlines: https://www.telegraph.co.uk/

Telegraph.co.uk and YouTube.com/TelegraphTV are websites of The Telegraph, the UK’s best-selling quality daily newspaper providing news and analysis on UK and world events, business, sport, lifestyle and culture.

Read more | >

Integrated Health Systems, in partnership with Maximum Life Foundation, is funding a trial to rejuvenate microglial cells using telomerase gene therapy. This trial is currently looking for ten patients with mild to moderate Alzheimer’s Disease. At this time five of the positions have been filled. The trial will be conducted in MONTEREY, Mexico. Treatment is …“Alzheimer’s Gene Therapy Human Study Seeks Volunteers”

Read more | >

Potential breakthrough technology for stem-cell based bone replacement

NEW YORK, May 22, 2019 /PRNewswire/ — EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for ramus continuity defects in the mandible. The ramus is a key component of the jaw bone which attaches to the muscles associated with chewing.

EB-CMF is a living anatomically correct bone graft manufactured from a patient’s own adipose derived stem cells. This eliminates the need to harvest bone from a patient’s body, potentially reducing pain, surgical and hospitalization time while creating a precision fit with the defect.

Read more | >